目的:探讨术前应用贝伐单抗辅助23 G玻璃体切除术治疗严重增殖性糖尿病视网膜病变的疗效.方法:回顾性分析本院2014-01/2015-06收治的严重增殖性糖尿病视网膜病变患者90例的病例资料,均为单眼病变.所有患者均行23 G玻璃体切除术联合眼内激光光凝,根据术前是否玻璃体腔注射贝伐单抗分为两组,术前未予以贝伐单抗注射者为对照组(40例),术前注射贝伐单抗者为研究组(50例).术后均随访6～12mo,比较两组患者手术时间、术后眼压、视力、黄斑厚度变化,并观察术后并发症情况.结果:两组患者术后整体最佳矫正视力(best corrected visual acuity,BCVA)变化,差异均存在统计学意义(P0.05).两组患者术后眼压变化,差异无统计学意义(P>0.05).两组患者术后黄斑厚度变化,差异有统计学意义(P0.05).研究组手术时间较对照组短,组间差异有统计学意义(P0. 05 ). There was no significant difference on postoperative IOP in both groups (P> 0. 05). There was significant difference between the two groups on macular thickness ( P 0. 05). The operation time of the study group was shorter than that of the control group, with significant difference between the two groups (P<0. 05). And the incidence of iatrogenic retinal tears and retinal detachment in study group were significantly lower than those in control group (P<0. 05).? CONCLUSION: Compared with single vitrectomy, preoperative bevacizumab assisted 23G vitrectomy combined with endolaser photocoagulation in the treatment of severe proliferative diabetic retinopathy has certain effect and short operation time, and can reduce intraoperative and postoperative complications.
展开▼
